This condition was first described by the dermatologist Winkler in 1915, who stated eight cases and later by Foerster, who again reported a further four cases. The exact occurrence of CNH remains unknown. This condition usually affects the helix of the pinna, though in some cases, the antihelix also may also be affected. For this reason, many researchers have suggested renaming the condition to chondrodermatitis nodularis auricularis.
Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chondrodermatitis-nodularis-helicis-market
Data Bridge Market Research analyses that the chondrodermatitis nodularis helicis market is expected to reach USD 658.4 million by 2030, which is USD 500 million in 2022, and is expected to undergo a CAGR of 3.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chondrodermatitis Nodularis Helicis (CNH) is a type of inflammatory condition that majorly affects the cartilage of ear and skin. It is also known as nodular chondrodermatitis, Winkler disease, and chondrodermatitis nodularis chronica helicis. A painful bump is witnessed on the cartilage of ear. It usually presents as a painful nodule which is surrounded by an area of erythema and often prevents the patient from sleeping on the affected side. Lesions are witnessed in both on the helix and on the antihelix.
North America is dominating the market in the forecast period because of the huge existence of large number of market players and growing clinical trials, well-developed healthcare sector and growing government support for RD in this region. Asia-Pacific is considered the most lucrative period because of the increased incidence of diseases and rising healthcare expenditure.
Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), AstraZeneca (U.K.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan)
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
